Immunome Inc Stock Price, News & Analysis

Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, April 10, 2025, at 12:45 p.m. Eastern Time.

The presentation will be accessible through a live audio webcast available on the Investor Relations section of Immunome's website. Following the live presentation, a replay will remain available for approximately 30 days.

Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has announced the granting of inducement awards to five new employees. The awards, approved by the Compensation Committee on April 1, 2025, consist of non-statutory stock options to purchase a total of 228,000 shares of common stock under the company's 2024 Inducement Plan.

The stock options have an exercise price of $6.26 per share, matching Immunome's closing price on April 1, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.

Immunome (NASDAQ: IMNM) announced its full year 2024 financial results and business updates. The company expects topline data from the Phase 3 RINGSIDE study of varegacestat for desmoid tumors in H2 2025. Key developments include the first patient dosing in Phase 1 trial of IM-1021 (ROR1-targeted ADC) and IND submission for IM-3050 (FAP-targeted radioligand therapy).

Financial highlights: Cash position of $217.3 million as of December 31, 2024, plus additional $172.5 million from January 2025 financing. The company reported R&D expenses of $129.5M, in-process R&D expenses of $152.3M, and G&A expenses of $33.0M for 2024. Net loss was $293.0M. Cash runway extends into 2027.

Pipeline progress includes three novel ADCs (IM-1617, IM-1340, IM-1335) in IND-enabling manufacturing and completion of RINGSIDE Part B enrollment in February 2024.

Immunome (NASDAQ: IMNM) has initiated patient dosing in its Phase 1 clinical trial of IM-1021, a ROR1-targeted ADC (Antibody-Drug Conjugate). The first-in-human trial is designed as an open-label, multicenter study focusing on dose escalation and expansion to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021.

The study will include patients with advanced B-cell lymphomas and advanced solid tumors. IM-1021 is an optimized ADC incorporating Immunome's proprietary TOP1 inhibitor, HC74, targeting patients with high unmet medical needs.

Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved non-statutory stock options for 49,000 shares of common stock to four new employees under its 2024 Inducement Plan.

The stock options were granted on March 3, 2025, with an exercise price of $8.94 per share, matching the company's closing price on that date. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.

Immunome (Nasdaq: IMNM), a biotechnology company developing first-in-class and best-in-class targeted cancer therapies, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:10 p.m. ET. The conference runs from March 3-5, 2025.

Additionally, Immunome will participate in the Leerink Partners Global Healthcare Conference 2025 on March 10, 2025, at 1:40 p.m. ET. This conference is scheduled for March 10-12, 2025.

Live webcast links for both presentations will be available on the events tab of Immunome's investor website, with replay links accessible for 30 days following the live broadcasts.

Aro Biotherapeutics announced a leadership transition as co-founder Susan Dillon, Ph.D., steps down from her position as president and CEO to continue as chair of the Board of Directors. The company has appointed Purnanand Sarma, Ph.D. as the new CEO and board member, effective immediately.

Dr. Sarma brings over three decades of pharmaceutical experience and will lead the development of Aro's pipeline of siRNA-conjugate medications, including ABX1100, a novel Centyrin-GYS1 siRNA drug conjugate for Pompe disease treatment. His background includes extensive drug development experience and success in IPOs, M&A, and company transactions, most recently serving as CEO of Immunome.

The transition comes as Aro advances its mission to develop targeted short-interfering RNA (siRNA) medicines, with its lead program already in clinical testing. The company's focus remains on creating a new class of targeted siRNA medicines for intractable diseases using their proprietary Centyrin technology.

Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on February 3, 2025. The awards consist of non-statutory stock options to purchase a total of 51,000 shares of common stock under the Company's 2024 Inducement Plan.

The stock options have an exercise price of $10.32 per share, matching the Company's closing price on February 3, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Immunome (NASDAQ: IMNM) has successfully closed its upsized public offering, selling 22,258,064 shares of common stock at $7.75 per share, including the full exercise of underwriters' option to purchase an additional 2,903,225 shares. The offering generated gross proceeds of $172.5 million before deducting underwriting discounts, commissions, and expenses.

The offering was managed by multiple financial institutions, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities acting as joint book-running managers, while Wedbush PacGrow served as lead manager. The offering was conducted under a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.